vs
Medpace Holdings, Inc.（MEDP）与OmniAb, Inc.（OABI）财务数据对比。点击上方公司名可切换其他公司
Medpace Holdings, Inc.的季度营收约是OmniAb, Inc.的84.6倍（$708.5M vs $8.4M）。Medpace Holdings, Inc.净利率更高（19.1% vs -169.3%，领先188.4%）。Medpace Holdings, Inc.同比增速更快（32.0% vs -22.5%）。Medpace Holdings, Inc.自由现金流更多（$188.1M vs $-5.7M）。过去两年OmniAb, Inc.的营收复合增速更高（48.4% vs 17.7%）
Medpace Holdings, Inc.是总部位于美国俄亥俄州辛辛那提的全球性临床研究机构（CRO），现有员工约6000人。公司采用全服务运营模式，可提供全球中心实验室、影像核心实验室、生物分析实验室服务，且在总部临床研究园区内设有I期临床试验单元。
OmniAb, Inc.是一家跨国生物技术企业，拥有专利转基因动物平台及全流程抗体发现解决方案，与全球制药和生物科技公司合作，加速肿瘤、自身免疫病等刚需医疗领域的全人源治疗抗体开发。
MEDP vs OABI — 直观对比
营收规模更大
MEDP
是对方的84.6倍
$8.4M
营收增速更快
MEDP
高出54.5%
-22.5%
净利率更高
MEDP
高出188.4%
-169.3%
自由现金流更多
MEDP
多$193.8M
$-5.7M
两年增速更快
OABI
近两年复合增速
17.7%
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $708.5M | $8.4M |
| 净利润 | $135.1M | $-14.2M |
| 毛利率 | — | — |
| 营业利润率 | 21.6% | -188.2% |
| 净利率 | 19.1% | -169.3% |
| 营收同比 | 32.0% | -22.5% |
| 净利润同比 | 15.5% | -8.5% |
| 每股收益（稀释后） | $4.65 | $-0.11 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收MEDPOABI
| Q4 25 | $708.5M | $8.4M | ||
| Q3 25 | $659.9M | $2.2M | ||
| Q2 25 | $603.3M | $3.9M | ||
| Q1 25 | $558.6M | $4.2M | ||
| Q4 24 | $536.6M | $10.8M | ||
| Q3 24 | $533.3M | $4.2M | ||
| Q2 24 | $528.1M | $7.6M | ||
| Q1 24 | $511.0M | $3.8M |
净利润MEDPOABI
| Q4 25 | $135.1M | $-14.2M | ||
| Q3 25 | $111.1M | $-16.5M | ||
| Q2 25 | $90.3M | $-15.9M | ||
| Q1 25 | $114.6M | $-18.2M | ||
| Q4 24 | $117.0M | $-13.1M | ||
| Q3 24 | $96.4M | $-16.4M | ||
| Q2 24 | $88.4M | $-13.6M | ||
| Q1 24 | $102.6M | $-19.0M |
营业利润率MEDPOABI
| Q4 25 | 21.6% | -188.2% | ||
| Q3 25 | 21.5% | -810.2% | ||
| Q2 25 | 20.9% | -416.2% | ||
| Q1 25 | 20.3% | -453.6% | ||
| Q4 24 | 23.4% | -147.0% | ||
| Q3 24 | 21.1% | -473.7% | ||
| Q2 24 | 19.9% | -214.1% | ||
| Q1 24 | 20.4% | -593.3% |
净利率MEDPOABI
| Q4 25 | 19.1% | -169.3% | ||
| Q3 25 | 16.8% | -738.1% | ||
| Q2 25 | 15.0% | -407.4% | ||
| Q1 25 | 20.5% | -438.1% | ||
| Q4 24 | 21.8% | -121.0% | ||
| Q3 24 | 18.1% | -392.4% | ||
| Q2 24 | 16.7% | -179.0% | ||
| Q1 24 | 20.1% | -498.8% |
每股收益（稀释后）MEDPOABI
| Q4 25 | $4.65 | $-0.11 | ||
| Q3 25 | $3.86 | $-0.14 | ||
| Q2 25 | $3.10 | $-0.15 | ||
| Q1 25 | $3.67 | $-0.17 | ||
| Q4 24 | $3.67 | $-0.13 | ||
| Q3 24 | $3.01 | $-0.16 | ||
| Q2 24 | $2.75 | $-0.13 | ||
| Q1 24 | $3.20 | $-0.19 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $497.0M | $25.5M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $459.1M | $267.0M |
| 总资产 | $2.0B | $300.9M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资MEDPOABI
| Q4 25 | $497.0M | $25.5M | ||
| Q3 25 | $285.4M | $28.5M | ||
| Q2 25 | $46.3M | $18.3M | ||
| Q1 25 | $441.4M | $10.9M | ||
| Q4 24 | $669.4M | $27.6M | ||
| Q3 24 | $656.9M | $27.2M | ||
| Q2 24 | $510.9M | $20.8M | ||
| Q1 24 | $407.0M | $19.1M |
股东权益MEDPOABI
| Q4 25 | $459.1M | $267.0M | ||
| Q3 25 | $293.6M | $277.4M | ||
| Q2 25 | $172.4M | $262.1M | ||
| Q1 25 | $593.6M | $273.5M | ||
| Q4 24 | $825.5M | $287.6M | ||
| Q3 24 | $881.4M | $291.7M | ||
| Q2 24 | $763.6M | $294.2M | ||
| Q1 24 | $671.5M | $301.4M |
总资产MEDPOABI
| Q4 25 | $2.0B | $300.9M | ||
| Q3 25 | $1.8B | $309.7M | ||
| Q2 25 | $1.6B | $295.7M | ||
| Q1 25 | $1.9B | $306.2M | ||
| Q4 24 | $2.1B | $325.6M | ||
| Q3 24 | $2.1B | $331.6M | ||
| Q2 24 | $1.9B | $337.3M | ||
| Q1 24 | $1.8B | $352.6M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $192.7M | $-5.7M |
| 自由现金流经营现金流 - 资本支出 | $188.1M | $-5.7M |
| 自由现金流率自由现金流/营收 | 26.6% | -67.8% |
| 资本支出强度资本支出/营收 | 0.6% | 0.1% |
| 现金转化率经营现金流/净利润 | 1.43× | — |
| 过去12个月自由现金流最近4个季度 | $681.9M | $-37.0M |
8季度趋势，按日历期对齐
经营现金流MEDPOABI
| Q4 25 | $192.7M | $-5.7M | ||
| Q3 25 | $246.2M | $-9.8M | ||
| Q2 25 | $148.5M | $-5.1M | ||
| Q1 25 | $125.8M | $-15.9M | ||
| Q4 24 | $190.7M | $-3.9M | ||
| Q3 24 | $149.1M | $-6.6M | ||
| Q2 24 | $116.4M | $-12.2M | ||
| Q1 24 | $152.7M | $-17.0M |
自由现金流MEDPOABI
| Q4 25 | $188.1M | $-5.7M | ||
| Q3 25 | $235.5M | $-9.9M | ||
| Q2 25 | $142.4M | $-5.3M | ||
| Q1 25 | $115.8M | $-16.1M | ||
| Q4 24 | $183.0M | $-3.9M | ||
| Q3 24 | $138.5M | $-6.7M | ||
| Q2 24 | $103.5M | $-12.9M | ||
| Q1 24 | $147.2M | $-18.0M |
自由现金流率MEDPOABI
| Q4 25 | 26.6% | -67.8% | ||
| Q3 25 | 35.7% | -444.2% | ||
| Q2 25 | 23.6% | -136.3% | ||
| Q1 25 | 20.7% | -387.1% | ||
| Q4 24 | 34.1% | -36.3% | ||
| Q3 24 | 26.0% | -161.3% | ||
| Q2 24 | 19.6% | -169.9% | ||
| Q1 24 | 28.8% | -472.5% |
资本支出强度MEDPOABI
| Q4 25 | 0.6% | 0.1% | ||
| Q3 25 | 1.6% | 8.1% | ||
| Q2 25 | 1.0% | 4.2% | ||
| Q1 25 | 1.8% | 5.0% | ||
| Q4 24 | 1.4% | 0.4% | ||
| Q3 24 | 2.0% | 3.6% | ||
| Q2 24 | 2.4% | 9.9% | ||
| Q1 24 | 1.1% | 24.4% |
现金转化率MEDPOABI
| Q4 25 | 1.43× | — | ||
| Q3 25 | 2.22× | — | ||
| Q2 25 | 1.65× | — | ||
| Q1 25 | 1.10× | — | ||
| Q4 24 | 1.63× | — | ||
| Q3 24 | 1.55× | — | ||
| Q2 24 | 1.32× | — | ||
| Q1 24 | 1.49× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
MEDP
| Metabolic | $249.8M | 35% |
| Oncology | $195.9M | 28% |
| Other | $88.3M | 12% |
| Central Nervous System | $73.2M | 10% |
| Cardiology | $63.0M | 9% |
| Antiviral And Anti Infective | $38.3M | 5% |
| Related Party | $10.3M | 1% |
OABI
暂无分部数据
